Brief: Exelixis says Detailed Results From Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib In Advanced Neuroendocrine Tumors Presented At ESMO 2023
22/10/2023 07:41
Oct 22 (Reuters) - Exelixis Inc EXEL.O :
* DETAILED RESULTS FROM PHASE 3 CABINET PIVOTAL TRIAL
EVALUATING
CABOZANTINIB IN ADVANCED NEUROENDOCRINE TUMORS PRESENTED AT ESMO
2023
* EXELIXIS - CABOZANTINIB COMPARED WITH PLACEBO REDUCED RISK
OF
DISEASE PROGRESSION/ DEATH IN PATIENTS WITH PANCREATIC NET AND
EXTRA-PANCREATIC NET
Source text for Eikon: ID:nBw7JNfLDa
Further company coverage: EXEL.O
((Reuters.Briefs@thomsonreuters.com;))